These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33961299)

  • 1. Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.
    Liu Q; Ou-Yang QG; Lin QM; Lu XR; Ma YQ; Li YH; Xu RA; Lin DD; Hu GX; Cai JP
    Fundam Clin Pharmacol; 2022 Feb; 36(1):150-159. PubMed ID: 33961299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4-Mediated Metabolism of Saxagliptin.
    Butrovich MA; Tang W; Boulton DW; Nolin TD; Sharma P
    J Clin Pharmacol; 2022 Aug; 62(8):1018-1029. PubMed ID: 35247279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
    Boulton DW
    Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
    Su H; Boulton DW; Barros A; Wang L; Cao K; Bonacorsi SJ; Iyer RA; Humphreys WG; Christopher LJ
    Drug Metab Dispos; 2012 Jul; 40(7):1345-56. PubMed ID: 22496391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro.
    Han M; Zhang X; Ye Z; Wang J; Qian J; Hu G; Cai J
    Chem Biol Interact; 2021 Dec; 350():109700. PubMed ID: 34648813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
    Tang PF; Zheng X; Hu XX; Yang CC; Chen Z; Qian JC; Cai JP; Hu GX
    Drug Des Devel Ther; 2020; 14():5129-5141. PubMed ID: 33262574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional assessment of
    Fang P; Tang PF; Xu RA; Zheng X; Wen J; Bao SS; Cai JP; Hu GX
    Drug Des Devel Ther; 2017; 11():3503-3510. PubMed ID: 29263648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential inhibition of sildenafil and macitentan on saxagliptin metabolism.
    Dai GX; Tan W; Shen Y; Lin D; Xu RA; Lin Q; Wei Z
    Toxicol Appl Pharmacol; 2024 May; 486():116934. PubMed ID: 38663673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/Pharmacodynamic modelling of Saxagliptin and its active metabolite, 5-hydroxy Saxagliptin in rats with Type 2 Diabetes Mellitus.
    Wang T; Tao T; Liu Y; Dong J; Ni S; Liu Y; Li Y; Xu N; Sun Z
    BMC Pharmacol Toxicol; 2024 Jun; 25(1):35. PubMed ID: 39103956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro.
    Yang CC; Zheng X; Liu TH; Wang CC; Tang PF; Chen Z; Zhang BW; Fang P; Hu GX; Cai JP
    Xenobiotica; 2019 Jan; 49(1):120-126. PubMed ID: 29394111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Recombinant CYP3A4 Variants on the Metabolism of Oxycodone In Vitro.
    Cai Y; Lin Q; Jin Z; Xia F; Ye Y; Xia Y; Papadimos TJ; Wang Q; Hu G; Cai J; Chen L
    Chem Res Toxicol; 2021 Jan; 34(1):103-109. PubMed ID: 33393779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro.
    Xie SL; Zhu X; Gao N; Lin Q; Chen C; Yang YJ; Cai JP; Hu GX; Xu RA
    Food Chem Toxicol; 2023 Nov; 181():114101. PubMed ID: 37863381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro.
    Li YH; Lin QM; Pang NH; Zhang XD; Huang HL; Cai JP; Hu GX
    Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):337-344. PubMed ID: 31058459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.
    Upreti VV; Boulton DW; Li L; Ching A; Su H; Lacreta FP; Patel CG
    Br J Clin Pharmacol; 2011 Jul; 72(1):92-102. PubMed ID: 21651615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional assessment of CYP3A4 and CYP2C19 genetic polymorphisms on the metabolism of clothianidin invitro.
    Hu Y; Ye Z; Wu H; Chen X; Xia H; Cai JP; Hu GX; Xu RA
    Chem Biol Interact; 2024 Aug; 399():111154. PubMed ID: 39025286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization of 27 CYP3A4 variants on macitentan metabolism in vitro.
    Li YH; Lu XR; Lin QM; Huang HL; Liang XL; Cai JP; Cui J; Hu GX
    J Pharm Pharmacol; 2019 Nov; 71(11):1677-1683. PubMed ID: 31441067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone.
    Li Q; Wang J; Wang ZL; Shen Y; Zhou Q; Liu YN; Hu GX; Cai JP; Xu RA
    Biomed Pharmacother; 2023 Dec; 168():115833. PubMed ID: 37935069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene Polymorphisms and Drug-Drug Interactions Determine the Metabolic Profile of Blonanserin.
    Ye F; Li X; Ni J; Xu X; Luo J; Zhong Y; Wang Y; Wang S; Zhang Y; Hu G; Qian J
    J Pharmacol Exp Ther; 2024 Jan; 388(1):190-200. PubMed ID: 37863485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism.
    Liu YN; Chen J; Wang J; Li Q; Hu GX; Cai JP; Lin G; Xu RA
    Arch Toxicol; 2023 Aug; 97(8):2133-2142. PubMed ID: 37209178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.